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Abstract
PURPOSE—This study investigated the efficacy and safety of vorinostat, a deacetylase (HDAC) 
inhibitor, in the treatment of laser-induced corneal haze following photorefractive keratectomy 
(PRK) in rabbits in vivo and transforming growth factor beta 1 (TGFβ1) -induced corneal fibrosis 
in vitro.
METHODS—Corneal haze in rabbits was produced with −9.00 diopters (D) PRK. Fibrosis in 
cultured human and rabbit corneal fibroblasts was activated with TGFβ1. Vorinostat (25 μm) was 
topically applied once for 5 minutes on rabbit cornea immediately after PRK for in vivo studies. 
Vorinostat (0 to 25 μm) was given to human/rabbit corneal fibroblasts for 5 minutes or 48 hours 
for in vitro studies. Slit-lamp microscopy, TUNEL assay, and trypan blue were used to determined 
vorinostat toxicity, whereas real-time polymerase chain reaction, immunocytochemistry, and 
immunoblotting were used to measure its efficacy.
RESULTS—Single 5-minute vorinostat (25 μm) topical application on the cornea following PRK 
significantly reduced corneal haze (P<.008) and fibrotic marker proteins (α-smooth muscle actin 
and f-actin; P<.001) without showing redness, swelling, or inflammation in rabbit eyes in vivo 
screened 4 weeks after PRK. Vorinostat reduced TGFβ1-induced fibrosis in human and rabbit 
corneas in vitro in a dose-dependent manner without altering cellular viability, phenotype, or 
proliferation.
CONCLUSIONS—Vorinostat is non-cytotoxic and safe for the eye and has potential to prevent 
laser-induced corneal haze in patients undergoing PRK for high myopia.
Correspondence: Rajiv R. Mohan, PhD, Mason Eye Institute, School of Medicine University of Missouri, 1 Hospital Dr, Columbia, 
MO 65212. Tel: 573.884.1449; Fax: 573.884.4100; mohanr@health.missouri.edu. 
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Approximately 80% of Americans older than 12 years have refractive errors.1 Laser eye 
surgeries such as photorefractive keratectomy (PRK), LASIK, and laser epithelial 
keratomileusis are frequently used to correct refractive errors and reduce dependency on 
spectacles or contact lenses.1–3 Photorefractive keratectomy is considered safest among 
refractive surgeries but is often associated with postoperative corneal haze in some cases.2,3 
Extensive research revealed that excessive cytokine and growth factor activity in the stroma 
following PRK induces abnormal corneal wound healing, extracellular matrix deposition, 
keratocyte transformation to myofibroblasts, and haze formation in the cornea.4–10 Among 
many cytokines, transforming growth factor beta 1 (TGFβ1) has been identified to play a 
major role in haze development, triggering transformation of quiescent keratocytes into 
corneal fibroblasts and myofibroblasts.6–10 Selective modulation of TGFβ1 has emerged as 
an effective strategy to control laser-induced corneal haze.7–10
Histone acetyltransferase and histone deacetylase (HDAC) are enzymes involved in 
epigenetic regulation of DNA transcriptional activity via acetylation-deacetylation of histone 
proteins including TGFβ1.11–14 Histone deacetylase inhibitors are shown to reduce TGFβ1-
induced collagen synthesis, myofibroblast formation, and fibrosis in many tissues including 
the cornea.12–14 In line with our hypothesis that epigenetic modulation is a novel and 
effective approach to treat corneal haze, we found significant inhibition of TGFβ1-mediated 
human corneal fibroblast transformation to myofibroblasts in vitro and PRK-induced corneal 
haze in rabbits in vivo by a potent HDAC inhibitor, trichostatin-A.14 Unfortunately, it is not 
approved for human use; however, in 2006 an analog of trichostatin-A, vorinostat 
(suberoylanilide hydroxamic acid) was approved by the United States Food and Drug 
Administration for medical use. Currently, vorinostat is used clinically to treat cancer in 
human patients. The purpose of this study was to evaluate the usefulness of vorinostat in 
preventing postoperative PRK corneal haze by testing its efficacy and toxicity using in vivo 
PRK corneal haze rabbit and in vitro TGFβ1-induced corneal fibrosis models.
MATERIALS AND METHODS
In Vitro Studies
Culture Conditions and Viability Assay—Donor human and rabbit corneas were used 
to generate primary corneal fibroblasts using minimal essential medium (MEM) 
supplemented with 10% serum. Corneal fibroblasts grown in the presence of TGFβ1 (1 
ng/mL) under serum-free conditions produced myofibroblasts. Short- and long-term 
vorinostat toxicity was examined by incubating cultures for 5 minutes and 48 hours, 
respectively. Cultures were seeded at 3×104 cells/well in 48 well culture plate in MEM 10% 
serum medium. When cells reached approximately 75% to 80% confluence, medium was 
switched to serum-free medium, and cells were incubated with/without vorinostat (0 to 25 
μm) for 5 minutes or 48 hours, allowed to reach ~90% confluence, trypsinized, and stained 
with 0.4% trypan blue solution. Toxicity was determined by counting blue and white cells 
following manufacturer instructions.
Quantitative Real-time Polymerase Chain Reaction—Total ribonucleic acid (RNA) 
and complementary deoxyribonucleic acid (cDNA) were prepared as described 
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previously.10,14 Real-time polymerase chain reaction (PCR) containing SYBR green, cDNA, 
forward/reverse primers for smooth muscle action (SMA)/fibronectin, and β-actin as 
housekeeping gene was performed as reported previously.10,14
Immunoblotting—Protein lysates were prepared and quantified by Bradford assay as 
reported previously.10,14 Samples were resolved on 4% to 12% sodium dodecyl sulfate 
polyacrylamide gel, transferred onto polyvinylidene fluoride membrane, incubated with 
SMA and β-actin or β-tubulin antibodies followed by alkaline phosphatase-conjugated anti-
mouse secondary antibodies and Nitro-blue tetrazolium chloride and 5-Bromo-4-chloro-3′-
indolyphosphate p-toluidine (NBT-BCIP) developing reagents.
Quantification and Statistical Analyses—Smooth muscle actin-positive cells in six 
randomly selected areas in corneal sections were counted and standard error means were 
calculated as reported previously.10,14 Statistical analysis was performed with two-way 
analysis of variance (ANOVA) and Bonferroni multiple comparisons for real-time PCR, 
one-way ANOVA followed by Tukey multiple comparisons for cellular viability, and one-
way ANOVA with Wilcoxon rank sum test for corneal haze. The value P<.05 was 
considered significant.
In Vivo Studies
Haze Generation, Vorinostat Treatment, Microscopy, and Tissue Collection—
The Institutional Animal Care and Use Committee approved the study and animals were 
treated in accordance with the Association for Research and Vision in Ophthalmology 
Statement for the use of animals in ophthalmic and vision research.
Twelve female New Zealand white rabbits were anesthetized with intramuscular ketamine 
(50 mg/kg) and xylazine (10 mg/kg) and one drop of 0.5% proparacaine was topically 
instilled in the cornea. To induce haze, −9.00-diopter (D) PRK with a 6-mm ablation zone 
was performed on the central corneal stroma with an excimer laser.10,14 Vorinostat (25 μm) 
or balanced salt solution was topically applied on the stroma for 5 minutes immediately after 
PRK. Contralateral eyes served as controls. Corneal health and haze levels in rabbits were 
gauged with slit-lamp and stereo-microscopy in a masked manner as reported 
previously.10,14 Rabbits were euthanized 4 weeks after PRK (pentobarbitone, 150 mg/kg) 
and corneas were subsequently excised and snap frozen in optical coherence tomography 
compound. Tissue sections (7 μm) were cut and maintained at −80°C.
Immunofluorescence Studies to Quantify Fibrosis and Toxicity—
Immunostaining and terminal deoxynucleotidyl transferase-mediated dUTP nick end 
labeling (TUNEL assay [ApopTag kit, Chemicon; Millipore Corp, Billerica, 
Massachusetts]) were performed by incubating rabbit corneal sections with α-SMA antibody 
or Alexa594-conjugated phalloidin or TdT Enzyme followed by secondary antibody or anti-
digoxigenin conjugate, and mounting in DAPI-containing medium following previously 
reported protocols.10,14
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RESULTS
Effect of Vorinostat on Corneal Fibroblast Viability and TGFβ1-induced Myofibroblast 
formation in vitro
Figure 1 shows vorinostat did not alter cellular viability of corneal fibroblasts significantly 
in a dose-dependent manner after 5 minutes of treatment. Rabbit corneal fibroblasts on 48-
hour vorinostat incubation under similar conditions showed similar results (data not shown).
Figure 2 shows the effect of single 5-minute vorinostat treatment on mRNA levels of SMA 
and fibronectin. Transforming growth factor beta 1-treated human corneal fibroblast 
produced a 9-fold increase in SMA (P<.001) and 3-fold increase in fibronectin mRNA 
levels (P<.01). Vorinostat treatment of 10 and 25 μm reduced TGFβ1-induced mRNA levels 
of SMA 80% (P<.001) and 86% (P<.001) and fibronectin mRNA 54% (P<.001) and 64% 
(P<.001), respectively.
Figure 3A shows anti-fibrotic effects of single 5-minute vorinostat treatment on corneal 
fibroblasts measured with western blot analysis. Transforming growth factor beta 1 
treatment significantly increased SMA protein levels and 5-minute 10- or 25-μm vorinostat 
dose decreased SMA protein by 45% or 50%, respectively (Fig 3B).
Figure 4 shows anti-fibrotic response of long-term (48 hours) vorinostat exposure in human 
corneas in vitro. The anti-fibrotic effects of vorinostat were dose-dependent as incremental 
decrease in TGFβ1-induced SMA expression was noted at increasing vorinostat doses with a 
complete absence of SMA at 10 and 25 μm (data not shown).
Microscopy and Immunohistochemical Measurements of the Effect of Vorinostat on 
Corneal Haze In Vivo
Figure 5 shows results of single topical application of 25 μm vorinostat on haze reduction in 
rabbit corneas 4 weeks after PRK evaluated with slit-lamp microscopy. Photorefractive 
keratectomy-treated rabbit corneas showed a mean haze score of 3±0.7 whereas vorinostat 
treatment demonstrated significant haze reduction (1.1±0.5; P<.008).
Figure 6 shows inhibitory effects of vorinostat on myofibroblast development measured with 
SMA and f-actin immunohistochemistry. High SMA and f-actin expression in PRK-treated 
rabbit corneas confirmed myofibroblast and haze formation (Figs 6A and 6C). Smooth 
muscle actin and f-actin staining was significantly decreased in rabbit corneas (Figs 6B and 
6D) that received single 5-minute vorinostat (25 μm) topically immediately after PRK, 
suggesting that vorinostat is an efficient anti-fibrotic agent for preventing corneal haze. 
Quantification of SMA in these corneas revealed that vorinostat inhibited SMA by 42% (P<.
001) in rabbit corneas in vivo (Fig 7).
Vorinostat Toxicity In Vivo
No detection of inflammation, redness, swelling, or discharge in the rabbit eye with slit-
lamp microscopy suggests that vorinostat is non-toxic to the rabbit eye. The effects of 
vorinostat on keratocyte death were analyzed with TUNEL assay. Figure 8 shows TUNEL 
staining observed in rabbit corneas collected 6 hours or 4 weeks after PRK with/without 
Tandon et al. Page 4
J Refract Surg. Author manuscript; available in PMC 2015 July 20.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
vorinostat (25 μm) application. Quantification of TUNEL+ cells in rabbit corneas with/
without vorinostat collected 6 hours or 4 weeks after PRK detected no significant 
differences in TUNEL+ cells, suggesting that topical vorinostat application is safe for the 
rabbit cornea in vivo. Detection of many TUNEL+ cells in the anterior stroma 6 hours after 
PRK or in corneal epithelium 4 weeks after PRK is not surprising and is consistent with 
earlier reports.5,13
DISCUSSION
Maintenance of corneal transparency is imperative for normal vision. Infection or injury to 
the cornea can initiate wound healing, resulting in scarring and vision loss.4–6 Corneal repair 
is orchestrated primarily by TGFβ1-mediated excess deposition of extracellular matrix along 
with the transformation of keratocytes to myofibroblasts, which causes corneal fibrosis and 
reduces optical clarity.6–10 The present study provides further support to our central 
hypothesis that epigenetic modulation in the cornea offers an effective approach to prevent 
corneal fibrosis in vivo.
The break in the epithelial barrier following refractive laser surgery exposes the stroma to 
many cytokines and growth factors released from corneal epithelium, tears, and transient 
inflammatory cell population often leading to excessive corneal healing and haze 
complication.6–9 Our recent RNA interference experiments suggest that TGFβ1 induces 
fibrosis in the cornea via Smad signaling (Mohan et al, unpublished data, September 2011) 
and histone acetylation is reported to regulate Smad-mediated gene expression.15 Thus, we 
tested the anti-fibrotic effect of vorinostat in a rabbit model of PRK-induced corneal haze. 
Our data demonstrate that a single topical prophylactic vorinostat treatment significantly 
decreased postoperative PRK corneal haze in vivo in rabbits as detected with slit-lamp 
microscopy and histological examinations. These results suggest that epigenetic modulation 
by HDAC inhibition can effectively serve as a means of preventing PRK-induced corneal 
haze.
At present, steroids and mitomycin C are used for the clinical management of corneal 
haze.3,5 The beneficial effects of steroids for inhibiting haze are inconclusive. Mitomycin C 
topical use after PRK is highly effective and generally provides excellent outcomes; 
however, it has been associated with multiple severe adverse effects including limbal and 
scleral necrosis, corneal endothelial damage, and loss of keratocytes.3,16–19 Our in vitro 
human cornea and in vivo rabbit cornea toxicity data suggest that vorinostat is safe for 
corneal application. Our results indicate that a single topical application of this agent has 
therapeutic potential for treatment of corneal fibrosis in vivo with no major side effects.
This study demonstrates that vorinostat can effectively prevent corneal haze by interrupting 
the biological effects of TGFβ1 and may have potential clinical applications for preventing 
corneal haze in patients undergoing PRK for high myopia.
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Figure 1. 
Dose-dependent effects of vorinostat 5-minute treatment on human corneal fibroblasts 
viability determined with trypan blue assay. None of the tested doses reduced cellular 
viability significantly.
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Figure 2. 
Effect of vorinostat treatment on smooth muscle actin (SMA) and fibronectin mRNA 
quantified with real-time polymerase chain reaction. Corneal fibroblast cultures grown in 
transforming growth factor beta 1 (TGFβ1) under serum-free conditions were exposed to 
vorinostat (10 or 25 μm) for 5 minutes. Vorinostat significantly reduced mRNA levels of 
SMA (80% to 86%, respectively) and fibronectin (54% to 64%, respectively). #P<.001 
compared to control; *P<.001 compared to TGFβ1.
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Figure 3. 
Effect of vorinostat on smooth muscle actin (SMA) inhibition determined with A) western 
blot and B) quantification. Human corneal fibroblasts grown in transforming growth factor 
beta 1 (TGFβ1) under serum-free conditions and exposed to vorinostat (10 or 25 μm) for 5 
minutes showed marked decrease in SMA (45% to 50%, respectively). Beta tubulin was 
used as a housekeeping gene. ζP<.001 compared to control; *P<.001 compared to TGFβ1.
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Figure 4. 
Dose-response effect of long-term vorinostat exposure on smooth muscle actin (SMA) 
reduction determined with A) immunocytochemistry and B) quantification. Rabbit corneal 
fibroblasts grown to 80% confluence were incubated with transforming growth factor beta 1 
(TGFβ1) with/without vorinostat (0 to 10 μm) under serum-free conditions for 48 hours. 
Vorinostat showed a significant dose-dependent decrease in SMA at all tested doses with 
highest inhibition at 10 μm. Original magnification ×100. *P<.05 no treatment vs TGFβ1, 
and **P<.05 TGFβ1 vs vorinostat.
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Figure 5. 
A) Representative slit-lamp microscopy images demonstrating haze density in rabbit corneas 
treated with photorefractive keratectomy (PRK) with/without vorinostat (25 μm) 4 weeks 
postoperatively. B) Haze quantification showed that a single 5-minute topical application of 
vorinostat significantly decreased haze in postoperative PRK corneas in vivo. *P<.008.
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Figure 6. 
Representative immunohistochemistry images 4 weeks after photorefractive keratectomy 
showing A, B) smooth muscle actin (SMA) and C, D) f-actin levels in corneas treated with/
without vorinostat (25 μm). Blue = DAPI-stained nuclei, Green = SMA+, red = f-actin+ 
cells. Vorinostat-treated corneas showed a significant decrease in SMA (B) and f-actin (D) 
compared to untreated corneas (A, C). *P<.001. Scale bar = 100 μm
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Figure 7. 
Quantification of smooth muscle actin (SMA)+ cells 4 weeks after photorefractive 
keratectomy (PRK) in corneas treated with/without vorinostat (25 μm). Vorinostat treatment 
significantly decreased SMA+ cells (*P<.001).
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Figure 8. 
Representative images showing TUNEL+ cells in rabbit corneas treated with/without 
vorinostat (25 μm) collected A, B) 6 hours or C, D) 4 weeks after photorefractive 
keratectomy (PRK). No significant differences in TUNEL+ cells in rabbit cornea with/
without vorinostat collected at early (6 hours) or end-point (4 weeks) suggests that a single 
5-minute, 25-μm topical dose of vorinostat is safe for the rabbit eye. The amounts of 
TUNEL+ cells detected 6 hours after PRK in the anterior stroma or 4 weeks after PRK in the 
epithelium are consistent with earlier reported findings.5,13 Red = TUNEL+ cells, Blue = 
DAPI-stained nuclei. Scale bar = 100 μm
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